Form 4: Corcept Therapeutics Executive Sean Maduck Reports Share Transactions

Corcept Therapeutics officer Sean Maduck reports acquiring and disposing of company stock, including shares withheld for tax obligations and new shares purchased under a company plan.

Summary

• Sean Maduck, an officer at Corcept Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On December 2, 2024, 295 shares were withheld to cover tax obligations related to vesting restricted stock units at a price of $57.68 per share.
• Also on December 2, 2024, Maduck acquired 265 shares through a purchase plan at $59.21 per share.
• Additionally, 265 shares were granted as restricted stock awards under the purchase plan.
• Maduck's total direct holdings increased to 85,318 shares after these transactions.
• He also has indirect holdings of 10,000 shares through Duckhill Capital, LLC and 10,000 shares through the Sean and Molly Maduck Living Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions are routine, but the purchase of shares by the executive suggests confidence in the company's prospects.

Positives

• The purchase of 265 shares by Sean Maduck at $59.21 per share indicates confidence in the company's future.
• The granting of 265 restricted stock awards under the purchase plan aligns Maduck's interests with the company's long-term performance.

Negatives

• The disposal of 295 shares to cover tax obligations, while routine, represents a reduction in Maduck's direct holdings.

Risks

• The vesting of restricted stock awards is contingent on Maduck remaining the beneficial owner of the purchase plan shares through the one-year anniversary of the grant date, which introduces a risk of forfeiture if he leaves the company or sells the shares before then.

Management Comments

• The power of attorney under which this form was signed is on file with the Commission.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading activities.
• The transactions reported are typical for executives who receive stock-based compensation and participate in company purchase plans.
• Similar filings are made by executives at comparable companies such as Exelixis, Inc. and Halozyme Therapeutics, Inc. when they engage in stock transactions.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive stock ownership.
• The purchase of shares by the executive may be viewed positively by investors.

Key Dates

Keywords

Corcept Therapeutics, Sean Maduck, Form 4, insider trading, stock transactions, restricted stock, beneficial ownership, executive compensation